ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 776

MMP7 and CXCL12: Two Promising Biomarkers in Lupus Nephritis

Sylvie Goletti1,2, Séverine Nieuwland3, Frédéric A. Houssiau2,3 and Bernard R. Lauwerys2,3, 1Service de Microbiologie, Cliniques Universitaires Saint-Luc, Brussels, Belgium, 2Pôle de pathologies rhumatismales systémiques et inflammatoires, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, 3Rheumatology Department, Cliniques universitaires Saint-Luc, Brussels, Belgium

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Biomarkers, lupus nephritis and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Systemic Lupus Erythematosus – Clinical Poster I: Clinical Manifestations and Comorbidity

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Lupus nephritis (LN) is one of the most serious complications of Systemic lupus erythematosus (SLE). Early diagnosis of renal impairment, combined with a strict follow-up of patients, is important to avoid morbidity and mortality. Yet, current conventional biomarkers (proteinuria, urinary protein/creatinine ratio, estimated glomerular filtration rate, serum anti-dsDNA antibody titers, serum complement levels) reflect systemic rather than renal activity of the disease, or, in the case of proteinuria, remain elevated as a consequence of chronic damage. The aim of this study was to identify new biomarkers reflecting intra-renal activation of immune cells and renal tubular cell damage, the main determinants of impaired renal function in LN.

Methods: Using transcriptomic data generated in LN versus control renal biopsies in the context of the PRECISESADS study, we identified candidate biomarkers that correlated with intra-renal infiltration by immune effectors or histological evidence of tubular damage, and were potentially secreted in the serum: IL34, MMP7, RANTES, SLA2, CXCL12, CCL19 and CCL21. We evaluated concentrations of these eight biomarkers in sixty-seven LN and in eight control sera. IL34, MMP7, RANTES and SLA2 were evaluated by ELISA and CXCL12, CCL19 and CCL21 using a Bioplex assay. Biological indices of disease activity were retrieved from the patients files.

Results: Serum IL34 (p value: 0.0288), MMP7, CXCL12, CCL19 and CCL21 (p values: <0.0001) concentrations were significantly higher in LN patients than in controls. Strikingly, serum MMP7 and CXCL12 concentrations were negatively correlated with eGFR (p values: 0.0135 and 0.0190 respectively), while this was not the case for anti-dsDNA antibody titers, serum C3 or urinary protein/creatinine ratio. Accordingly, serum MMP7 and CXCL12 concentrations were significantly higher in patients with an eGFR < 50 mL/min/1.73 m2 compared to > 50 mL/min/1.73 m2 (p values: 0.0020 and 0.0336, respectively).

Conclusion: Adequate management of LN will be served by the identification of biomarkers reflecting intra-renal rather than systemic inflammation. By opposition to conventional biomarkers, MMP7 and CXCL12, which are produced in the kidney itself, displayed a significant negative correlation with eGFR in LN. Confirmation of these results in independent cohorts of samples is pending.


Disclosure: S. Goletti, None; S. Nieuwland, None; F. A. Houssiau, None; B. R. Lauwerys, None.

To cite this abstract in AMA style:

Goletti S, Nieuwland S, Houssiau FA, Lauwerys BR. MMP7 and CXCL12: Two Promising Biomarkers in Lupus Nephritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/mmp7-and-cxcl12-two-promising-biomarkers-in-lupus-nephritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mmp7-and-cxcl12-two-promising-biomarkers-in-lupus-nephritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology